Continuing reassessment of the risks of rythropoiesis-stimulating agents in patients with cancer

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3242-3247

  Juneja, Vinni ^a   Keegan, Patricia ^a   Gootenberg, Joseph E ^a   Rothmann, Mark D ^a   Shen, Yuan Li ^a   Lee, Kyung Y ^a   Weiss, Karen D ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CISPLATIN; ETOPOSIDE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; DRUG USE; HUMAN; LUNG CANCER; NEOPLASM; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOSIS; CHEMICALLY INDUCED DISORDER; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; HEMATINICS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 50349088773     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1872     Document Type: Article

References (14)

1. Blajchman MA, Vamvakas EC. The continuing risk of transfusion transmitted infections. N Engl J Med 2006;355:1303-5.
2. O'Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007;47:316-25.
3. Sheppard CA, Logdberg LE, Zimring JC, Hillyer CD. Transfusion-related acute lung injury. Hematol Oncol Clin N Am 2007;21:163-76.
4. Dzik WH. Emily Cooley Lecture 2002: transfusion safety in the hospital. Transfusion 2003;43:1190-9.
5. Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev 2005;18:195-204.
6. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. N Engl J Med 1999;340:438-47.
7. Williamson LM. Transfusion associated graft versus host disease and its prevention. Heart 1998;80:211 -2.
8. Seed CR, Kiely P, Keller AJ. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lym-photrophic virus. Intern Med J 2005;35:592-8.
9. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
10. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving firstline chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
11. Wright JR, Ung YC. Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small cell lung cancer with disease related anemia. J Clin Oncol 2007;25:1027-32.
12. Grote T Yeilding AL, Castillo R, et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005;22:9377-86.
13. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60.
14. Goldberg P. Danish researchers post long-awaited Aranesp results-ever so discreetly. Cancer Lett 2007;33:1 -6.